Table 3.

Results of unadjusted and adjusted logistic regression analyses of mortality and major adverse events, by statin use and statin intensity

	Unadjusted		Adjusted*
	Odds ratio	P	Odds ratio	P
Mortality*
No statin	1·00 (reference)		1·00 (reference)
Statin use	0·40 (0·30, 0·51)	< 0·001	0·41 (0·31, 0·54)	< 0·001
Statin intensity
Low	0·50 (0·25, 0·99)	0·046	0·49 (0·24, 0·97)	0·041
Moderate	0·32 (0·23, 0·45)	< 0·001	0·34 (0·24, 0·47)	< 0·001
High	0·53 (0·33, 0·84)	0·007	0·56 (0·34, 0·90)	0·017
Supratherapeutic	0·50 (0·28, 0·91)	0·024	0·52 (0·28, 0·95)	0·035
Major adverse event†
No statin	1·00 (reference)		1·00 (reference)
Statin use	1·02 (0·93, 1·13)	0·678	0·90 (0·81, 1·00)	0·058
Statin intensity
Low	0·99 (0·77, 1·27)	0·937	0·85 (0·66, 1·11)	0·232
Moderate	0·97 (0·86, 1·08)	0·551	0·86 (0·76, 0·96)	0·011
High	1·05 (0·88, 1·26)	0·555	0·94 (0·78, 1·14)	0·519
Supratherapeutic	1·33 (1·07, 1·65)	0·009	1·19 (0·95, 1·50)	0·132

Values in parentheses are 95 per cent confidence intervals.

^*The logistic regression model for mortality was adjusted for patient age and sex, beta‐blocker use, chronic kidney disease, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease and admission status (elective, urgency or emergency).

^†The model for major adverse events was adjusted for patient age, sex, race, primary payer, beta‐blocker use, chronic kidney disease, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, history of acute myocardial infarction, admission status (elective, urgent or emergency), teaching and urban hospital status, and physician volume. In a post hoc analysis, using low‐intensity statins as a reference group, moderate, high and supratherapeutic statin intensity did not have a lower odds of death or major adverse events compared with low intensity.